Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stagesShow others and affiliations
2026 (English)In: Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, E-ISSN 1468-330X, Vol. 97, no 4, p. 316-324Article in journal (Refereed) Published
Abstract [en]
Background Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia, yet it remains under-recognised and misdiagnosed, which delays treatment, causes inaccurate prognosis and limits research opportunities. Imaging with 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is a supportive DLB biomarker. We evaluated a multivariate, quantifiable metabolic network biomarker, termed DLB-related pattern (DLBRP), for its further clinical translation across centres and disease stages. Methods We analysed demographic, clinical and FDG PET imaging data of 1180 participants from 14 tertiary centres and two multicentre datasets. We included 379 DLB, 28 mild cognitive impairment-LB (MCI-LB), 195 dementia due to Alzheimer's disease (ADD), 172 MCI-AD without alpha-synuclein co-pathology (MCI-AD-S-), and 73 MCI-AD with alpha-synuclein co-pathology (S+) patients, along with a comparative group of 333 normal controls (NCs). From the scans, we calculated the expression of DLBRP, AD-related pattern (ADRP) and Parkinson's disease-related pattern (PDRP) and compared them across groups. DLBRP scores were correlated with clinical measurements. Results Across independent cohorts, DLBRP robustly distinguished DLB from NCs (sensitivity >89%, specificity >90%), and scores correlated with Unified Parkinson's Disease Rating Scale Part III and independently predicted Mini-Mental State Examination. DLBRP was elevated already in MCI-LB. In a small longitudinal dataset, we observed steady increases in DLBRP expression with scores exceeding the diagnostic threshold prior to dementia onset. DLBRP and PDRP discriminated DLB from ADD (sensitivity, 74%-90%; specificity, 80%). In MCI-AD groups, ADRP was expressed, whereas DLBRP and PDRP were increased only in MCI-AD-S+, although comparatively less than in MCI-LB. Conclusions This study demonstrates the value of DLBRP in diagnosing prodromal and manifest DLB and distinguishing them from their AD counterparts. While overlap between patterns may reflect actual co-pathology, this possibility cannot be accepted without thorough pathological confirmation. The current findings support the use of DLBRP in patient evaluation and in future trial design.
Place, publisher, year, edition, pages
BMJ PUBLISHING GROUP , 2026. Vol. 97, no 4, p. 316-324
Keywords [en]
LEWY BODY DEMENTIA; ALZHEIMER'S DISEASE; PET, FUNCTIONAL IMAGING
National Category
Neurology
Identifiers
URN: urn:nbn:se:liu:diva-220481DOI: 10.1136/jnnp-2025-336935ISI: 001633631900001PubMedID: 41344886Scopus ID: 2-s2.0-105024206090OAI: oai:DiVA.org:liu-220481DiVA, id: diva2:2029906
Note
Funding Agencies|Pfizer Inc. [N/A]; Meso Scale Diagnostics, LLC [N/A]; National Institutes of Health [U01 AG024904]; GE Healthcare [N/A]; Foundation for Geriatric Diseases [N/A]; Eli Lilly and Company [N/A]; Transition Therapeutics [N/A]; Merck Co., Inc. [N/A]; ALF Medicine [FoUI-962240, FoUI-987534]; Novartis Pharmaceuticals Corporation [N/A]; CIMED [20200505]; Takeda Pharmaceutical Company [N/A]; CereSpir, Inc [N/A]; Janssen [N/A]; Hjrnfonden [FO2021-0131, FO2022-0175, FO2023-0261]; BioClinica [N/A]; Araclon Biotech [N/A]; Alzheimer's Drug Discovery Foundation [N/A]; Bureau of Educational and Cultural Affairs [Fulbright Visiting Scholar Program]; Bristol Myers Squibb Foundation [N/A]; Vetenskapsrdet [2022-00916]; Johnson Johnson [N/A]; Elan Pharmaceuticals, Inc. [N/A]; The Slovenian Research Agency (ARRS) [J3-60059, J7-2600, J7-3150, P1-0389]; Eisai [N/A]; the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering [N/A]; the Swedish Dementia Foundation (Demensfonden), the Gamla Tjnarinnor Foundation, the Gun och Bertil Stohnes Foundation, the ke Wiberg Foundation [N/A]; AbbVie [N/A]; Swedish Alzheimer Foundation [AF-968032, AF-980580, AF-994058]; Department of Defense [W81XWH-12-2-0012]; Medizinische Fakultt der Albert-Ludwigs-Universitt Freiburg [Berta-Ottenstein program]; Genentech, Inc. [N/A]; Alzheimer's Association [N/A]; Biogen [N/A]; Germany's Excellence Strategy [390857198, EXC 2145]; F. Hoffmann-La Roche Ltd [N/A]; Lundbeck [N/A]
2026-01-192026-01-192026-05-12